JP7267014B2 - 癌ワクチンにおける使用のためのｐｄｌ１ペプチド - Google Patents

癌ワクチンにおける使用のためのｐｄｌ１ペプチド Download PDF

Info

Publication number
JP7267014B2
JP7267014B2 JP2018566600A JP2018566600A JP7267014B2 JP 7267014 B2 JP7267014 B2 JP 7267014B2 JP 2018566600 A JP2018566600 A JP 2018566600A JP 2018566600 A JP2018566600 A JP 2018566600A JP 7267014 B2 JP7267014 B2 JP 7267014B2
Authority
JP
Japan
Prior art keywords
seq
cells
peptide fragment
peptide
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018566600A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019527676A (ja
JP2019527676A5 (OSRAM
Inventor
ハルド アンデルセン，マッズ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IO Biotech ApS
Original Assignee
IO Biotech ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IO Biotech ApS filed Critical IO Biotech ApS
Publication of JP2019527676A publication Critical patent/JP2019527676A/ja
Publication of JP2019527676A5 publication Critical patent/JP2019527676A5/ja
Application granted granted Critical
Publication of JP7267014B2 publication Critical patent/JP7267014B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2018566600A 2016-06-21 2017-06-20 癌ワクチンにおける使用のためのｐｄｌ１ペプチド Active JP7267014B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16175397 2016-06-21
EP16175397.5 2016-06-21
PCT/EP2017/065122 WO2017220602A1 (en) 2016-06-21 2017-06-20 Pdl1 peptides for use in cancer vaccines

Publications (3)

Publication Number Publication Date
JP2019527676A JP2019527676A (ja) 2019-10-03
JP2019527676A5 JP2019527676A5 (OSRAM) 2020-07-30
JP7267014B2 true JP7267014B2 (ja) 2023-05-01

Family

ID=56363704

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018566600A Active JP7267014B2 (ja) 2016-06-21 2017-06-20 癌ワクチンにおける使用のためのｐｄｌ１ペプチド

Country Status (5)

Country Link
US (3) US20200339659A1 (OSRAM)
EP (1) EP3472180A1 (OSRAM)
JP (1) JP7267014B2 (OSRAM)
CN (1) CN109641936B (OSRAM)
WO (1) WO2017220602A1 (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200339659A1 (en) 2016-06-21 2020-10-29 Io Biotech Aps Pdl1 peptides for use in cancer vaccines
WO2019136531A1 (en) * 2018-01-15 2019-07-18 University Of Canberra Proteinaceous molecules and uses therefor
MX2021005980A (es) 2018-11-21 2021-08-11 Mayo Found Medical Education & Res Adenovirus y metodos para usar adenovirus.
WO2020181402A1 (zh) * 2019-03-10 2020-09-17 胡西木 一种抗肿瘤多肽及其应用
US20230227533A1 (en) * 2020-04-18 2023-07-20 Beijing Zeqin Biomedical Co., Ltd Fusion peptide for treating autoimmune disease
US20250327041A1 (en) 2022-02-24 2025-10-23 Io Biotech Aps Nucleotide delivery of cancer therapy

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001034768A2 (en) 1999-11-09 2001-05-17 Human Genome Sciences, Inc. 15 human secreted proteins
US20100055111A1 (en) 2007-02-14 2010-03-04 Med. College Of Georgia Research Institute, Inc. Indoleamine 2,3-dioxygenase, pd-1/pd-l pathways, and ctla4 pathways in the activation of regulatory t cells
JP2013014583A (ja) 2011-06-10 2013-01-24 Anges Mg Inc メチオニン・スルホキシドを含む新規ポリペプチド
JP2014534202A (ja) 2011-10-17 2014-12-18 ヘルレフ ホスピタルＨｅｒｌｅｖ Ｈｏｓｐｉｔａｌ Ｐｄ−ｌ１に基づく免疫療法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
GB8707398D0 (en) * 1987-03-27 1987-04-29 Coopers Animal Health Biologically active molecules
CA2442066C (en) 2001-04-02 2005-11-01 Wyeth Pd-1, a receptor for b7-4, and uses therefor
WO2002086083A2 (en) 2001-04-20 2002-10-31 Mayo Foundation For Medical Education And Research Methods of enhancing cell responsiveness
US7595048B2 (en) 2002-07-03 2009-09-29 Ono Pharmaceutical Co., Ltd. Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1
RS54271B1 (sr) 2005-07-01 2016-02-29 E. R. Squibb & Sons, L.L.C. Humana monoklonska antitela za ligand programirane smrti 1 (pd-l1)
JP2010504356A (ja) 2006-09-20 2010-02-12 ザ ジョンズ ホプキンス ユニバーシティー 抗ｂ７−ｈ１抗体を用いた癌及び感染性疾患の組合せ療法
US20120269806A1 (en) 2007-08-21 2012-10-25 The General Hospital Corporation Methods of inducing tolerance
CN102203125A (zh) 2008-08-25 2011-09-28 安普利穆尼股份有限公司 Pd-1拮抗剂及其使用方法
JP2013512251A (ja) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
IL323000A (en) 2010-03-05 2025-10-01 Univ Johns Hopkins Compositions and methods for antibodies and fusion proteins targeted for immune modulation
US20200339659A1 (en) 2016-06-21 2020-10-29 Io Biotech Aps Pdl1 peptides for use in cancer vaccines
US20200299401A1 (en) * 2017-11-24 2020-09-24 Io Biotech Aps Enhancement of antibody-dependent cell-mediated cytotoxicity (adcc)

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001034768A2 (en) 1999-11-09 2001-05-17 Human Genome Sciences, Inc. 15 human secreted proteins
US20100055111A1 (en) 2007-02-14 2010-03-04 Med. College Of Georgia Research Institute, Inc. Indoleamine 2,3-dioxygenase, pd-1/pd-l pathways, and ctla4 pathways in the activation of regulatory t cells
JP2013014583A (ja) 2011-06-10 2013-01-24 Anges Mg Inc メチオニン・スルホキシドを含む新規ポリペプチド
JP2014534202A (ja) 2011-10-17 2014-12-18 ヘルレフ ホスピタルＨｅｒｌｅｖ Ｈｏｓｐｉｔａｌ Ｐｄ−ｌ１に基づく免疫療法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MUNIR S，CANCER RESEARCH，米国，2013年01月17日，VOL:73, NR:6，PAGE(S):1764 - 1776，https://cancerres.aacrjournals.org/content/73/6/1764.full-text.pdf

Also Published As

Publication number Publication date
JP2019527676A (ja) 2019-10-03
US20250230218A1 (en) 2025-07-17
CN109641936B (zh) 2023-11-28
US20220372108A1 (en) 2022-11-24
US20200339659A1 (en) 2020-10-29
WO2017220602A1 (en) 2017-12-28
US12187782B2 (en) 2025-01-07
EP3472180A1 (en) 2019-04-24
CN109641936A (zh) 2019-04-16

Similar Documents

Publication Publication Date Title
US12187782B2 (en) PDL1 peptides for use in cancer vaccines
ES2432357T3 (es) Anticuerpos enteramente humanos contra 4-1BB humano (CD137)
KR101689210B1 (ko) 백신 조성물 및 방법
WO2016179573A1 (en) Variant survivin vaccine for treatment of cancer
AU2012286690A1 (en) Dendritic cell (DC)-vaccine therapy for pancreatic cancer
US20250236658A1 (en) Pdl2 compounds
AU2010298519B2 (en) Identification of antigenic peptides from multiple myeloma cells
JP7211938B2 (ja) 免疫原性アルギナーゼペプチド
US20220088162A1 (en) Heterologous Prime Boost Vaccine
WO2021074389A1 (en) Immunogenic compounds for treatment of adrenal cancer
JP2022507373A (ja) 免疫原性アルギナーゼ２ポリペプチド
Masuko et al. Artificially synthesized helper/killer-hybrid epitope long peptide (H/K-HELP): preparation and immunological analysis of vaccine efficacy
NL2034658B1 (en) TIMP3-derived TEIPP neoantigens and uses thereof
KR20160127711A (ko) 유비퀴티닐화 단백질
HK40030417A (en) T cell receptors for immunotherapy
Zabaleta et al. Helper cell-independent antitumor activity of potent CD8+ T cell epitope peptide vaccines is dependent upon CD40L
Xiao Dendritic cell-specific vaccine utilizing antibody-mimetic ligand and lentivector system
HK1224680A1 (en) Novel four-ctl epitope-joined peptide

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20190411

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190411

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200616

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200616

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210622

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210921

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220104

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220704

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221011

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230209

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230209

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230216

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230221

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230328

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230419

R150 Certificate of patent or registration of utility model

Ref document number: 7267014

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150